Journal
INFLAMMATORY BOWEL DISEASES
Volume 18, Issue 1, Pages 10-16Publisher
WILEY-BLACKWELL
DOI: 10.1002/ibd.21707
Keywords
Crohn's disease; inflammatory bowel disease; anti-TNFa therapy; adalimumab
Categories
Funding
- American Gastroenterological Association Foundation
- Digestive Disease Research Core Center of the University of Chicago [DK42086]
- Centocor, Inc.
- Abbott Laboratories
Ask authors/readers for more resources
Background: Pivotal trials for adalimumab (ADA) demonstrated effectiveness versus placebo for induction and maintenance of remission in moderate to severely active Crohn's disease (CD). Although the approved maintenance regimen in the U.S. is 40 mg subcutaneously every 14 days, some patients require dose-escalation ([DE] either an increase in the delivered dose or decrease in the interval of treatment). Our objective was to determine which patient-, disease-, and therapy-related factors were associated with DE in CD patients treated with ADA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available